adalimumab vs infliximab
PlainMeds reviewed this comparison against our methodology in August 2026. It places FDA and CMS record fields side by side, without recommending either medication.
Side-by-side comparison of adalimumab and infliximab. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
Humira
Remicade
Idacio is a medicine that blocks a protein called TNF. It is used to treat several diseases, including arthritis and Crohn's disease.
Inflectra is a medicine that blocks a protein called TNF. It is used to treat autoimmune diseases and reduce inflammation.
Idacio can help adults with rheumatoid arthritis by reducing joint pain and damage. It can also help children (2 years and older) with juvenile idiopathic arthritis. Idacio treats psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa and uveitis.
Inflectra treats Crohn's disease in adults and children (6+). It helps reduce symptoms and keep the disease under control. It also treats ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis.
Idacio works by blocking a protein in your body called tumor necrosis factor (TNF). TNF can cause inflammation and damage in certain diseases. By blocking TNF, Idacio can reduce these symptoms.
Inflectra blocks a protein in your body called tumor necrosis factor (TNF). TNF can cause inflammation and damage in autoimmune diseases. By blocking TNF, Inflectra can reduce inflammation and improve symptoms.
- • Infections (like colds or sinus infections)
- • Injection site reactions (redness, itching, pain, or swelling)
- • Headache
- • Rash
- • Infections (like colds, sinus infections, and sore throat)
- • Infusion-related reactions
- • Headache
- • Abdominal pain
- Pain 49,062
- Arthralgia 48,039
- Injection Site Pain 47,251
- Fatigue 39,111
- Rheumatoid Arthritis 35,573
- Infusion Related Reaction 18,648
- Condition Aggravated 18,301
- Rheumatoid Arthritis 18,136
- Pain 18,107
- Arthralgia 16,853
Idacio can increase your risk of serious infections that could lead to hospitalization or death. Tell your doctor if you have any infections before starting Idacio. Idacio may also increase your risk of certain cancers, including lymphoma. Children and teens taking TNF blockers like Idacio have developed rare, aggressive cancers.
Inflectra can increase your risk of serious infections that may lead to hospitalization or death. Tell your doctor if you have any infection symptoms. You should be tested for tuberculosis (TB) before starting Inflectra. Some people, especially children and young adults, have developed cancers like lymphoma while taking TNF blockers. Some of these cancers have been fatal.
Tell your doctor if you are pregnant or plan to become pregnant. Idacio can cross the placenta and may affect your baby's immune system. Talk to your doctor about vaccines for your baby if you took Idacio during pregnancy.
Tell your doctor if you are pregnant or plan to become pregnant. Inflectra can pass to your baby during pregnancy, mainly in the third trimester. Live vaccines are not recommended for at least 6 months after birth for babies exposed to Inflectra in the womb.
Also Compare, Nearby Drugs
Compare adalimumab with
Compare infliximab with
How to Read This adalimumab vs infliximab Comparison
adalimumab is classified in the TNF-Alpha Inhibitor (Biologic) drug class, while infliximab sits within the TNF-Alpha Inhibitor (Biologic) class. Because both drugs share the same classification, they are often considered interchangeable in theory, but clinical outcomes rarely track that cleanly. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, adalimumab has 219,036 submissions while infliximab has 90,045. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. No direct interaction between these two drugs is listed in our FDA-derived dataset, though co-prescription still warrants pharmacist review. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for adalimumab or infliximab.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.